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& Abstract
Introduction: Neuropathic pain is a common symptom,
present in 39% of the patients with cancer pain. Treating
this type of pain is challenging, as this patient group is often
frail and has comorbidities which increase the risk of side
events and hence influences their quality of life. Clinical
practice guidelines (CPGs) can be helpful for clinicians,
especially when scientific evidence is uncertain or weak. In
this study, we focused on the quality of the review of the
literature used in treatment recommendations in the selected
European CPGs.
Methods: In a previous study, 9 CPGs from European
countries that contained at least one paragraph on treatment
for neuropathic pain in cancer were included. Recommenda-
tions with their grade (according SIGN 55 classification) and
supporting literature (first author, patients’ population, year
and type of publication) were compared between CPGs.
Results: In all CPGs, amitriptylin was mentioned as the drug
of first choice. Six guidelines proposed also gabapentinoids.
Only 30 of the 163 citations (18%) were based on studies in
patients with cancer. Seven CPGs did not argue the indirect
evidence due to extrapolation of study results from non-
cancer to patients with cancer.
Conclusion: The majority of guideline development groups
extrapolated their results from non-cancer publications to
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formulate recommendations. Consequently, these guidelines
fail to address important issues such as altered kinetics and
side effect profiles in these patients. We recommend creating
specific recommendations by an international expert group
for the treatment for neuropathic pain in patients with
cancer supported by targeted research in patients with
cancer. &
Key Words: neuralgia, cancer, neuropathic pain, evidence-
based medicine, clinical practice guidelines
INTRODUCTION
In Europe, the prevalence of moderate to severe pain in
patients with cancer is about 56%.1 Pain in patients with
cancer is often related to a combination of nociceptive
and neuropathic mechanisms. In a systematic review of
Bennett, the prevalence of neuropathic pain in patients
with cancer was found to be 19%. The combination of
mixed pain (nociceptive pain) was found to be 39.7%.2
Using theWorld Health Organization (WHO), analgesic
ladder for cancer pain relief resolves the nociceptive
component in 80% of the treated patients. However, the
neuropathic pain component is often more difficult to
treat.3 Not all drugs are specifically registered for the
treatment for neuropathic pain in patients with cancer in
European countries. This implies that most specific
drugs used for the treatment for neuropathic pain in
patients with cancer are used off-label.4 Most clinical
research concerning neuropathic pain treatment is
performed in patients with diabetic painful neuropathy
(DPN) or post-herpetic neuropathy (PHN) and infre-
quently in patients with neuropathic cancer pain.
Patients with cancer suffering from neuropathic pain
should be considered different from patients with
neuropathic pain in other context for several reasons.5
Firstly, approximately 50% of the patients with cancer
suffering from neuropathic pain also have nociceptive or
visceral pain, in contrast to patients suffering from
neuropathic pain in another context.6 Secondly, they are
more fragile with a potential life-threatening disease.
Thirdly, in patients with cancer, the effect size of
antiepileptic or antidepressant drug, used in addition
to the opioids, is less than that seen in patients with non-
cancer neuropathic pain.2
Clinical practice guidelines (CPGs) were created to
improve the treatment for a specific condition and are
supposed to be based on the latest evidence. Concerning
neuropathic pain in patients with cancer, a recent
statement of the International Association for the Study
of the Pain (IASP) emphasized that the extrapolation of
data from studies of other neuropathic conditions to
patientswith cancer-induced neuropathic pain is far from
straightforward.5 In parallel of the evaluation of recom-
mendations on neuropathic pain diagnosis and assess-
ment in patients with cancer,7 the aim of this study is to
compare recommendations proposed in national CPGs
from Europe concerning the treatment for neuropathic
pain in patients with cancer and their evidence grading.
METHODS
Study Design
The relation between chosen references, their level of
evidence, and the recommendations given in CPGs was
systematically studied.
Selection of Guidelines
A European inventory of CPGs was performed with the
support of the European Federation of the IASP Chap-
ters (EFIC).7 Nine CPGs were included, and this
material was used for this study. All CPGs were
published between 2006 and 20098–16 from France
(1), Italy (2), the Netherlands (2), Norway (2), Spain (1),
and the United Kingdom (1). Four were developed under
responsibility of a national organization specialized in
guideline development.9,12,14,15 Five were developed by
professional societies (oncology, palliative care, or pain
societies).8,10,11,13,16 One was developed by an Italian
regional health organization (Italy 2).8 None of the
guidelines were developed solely or specifically for the
treatment for neuropathic pain in patients with cancer.
Collection of the Data and Analysis
We developed a procedure to extract recommendations
about how to treat neuropathic pain in patients with
cancer. Recommendations were defined as “statements
that promote or advocate a particular course of action in
clinical care”.17 These treatment recommendations were
extracted together with the related references and used
as evidence in each CPG. The references were catego-
rized by study design (meta-analysis and systematic
review; randomized controlled trial [RCT] with  60
patients; RCT with < 60 patients; CPG; other) and topic
(neuropathic pain, cancer neuropathic pain, cancer pain,
acute and chronic pain, and other). Each reference was
also considered according to the country of the first
author and/or of the work group, journal, and year of
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publication. A reference used in at least two CPGs was a
shared reference.
Recommendations were analyzed considering drugs
proposed to treat neuropathic pain in patients with
cancer in each CPG. We focused our analysis on three
main drugs: amitriptyline; gabapentin; and pregabalin.
For each of these three drugs, we collected positioning in
therapeutic strategy (first or second line), start and
maximumdoses, titration scheme,mentioned side effects
and contra-indications, the level of evidence, and the
grade of the recommendation, according to the Scottish
intercollegiate guidelines network (SIGN) 50 criteria.13
Statistical Analysis
Analysis was performed with SPSS 16.0 (IBM, Somers,
NY, U.S.A.) using descriptives and frequencies.
RESULTS
Pages Specifically Dedicated to the Treatment for
Neuropathic Pain in Patients with Cancer
The nine included CPGs represented 1,480 pages with
only 53.5 (4%) pages focusing on the treatment for
neuropathic pain in patients with cancer. The sections
about the treatment for neuropathic pain in patients
with cancer ranged between half a page (Spain) to 37
pages (France) (0.2% to 22%, mostly bellow 5%).
Characteristics of the References Related to
Recommendations Selected in the “Neuropathic Pain in
Patients with Cancer” Treatment Section of CPG
Our work collected a total of 163 references related to
recommendations selected in the “neuropathic pain in
patients with cancer” treatment section of CPGs.
Among these, a majority (116/163: 71%) were about
neuropathic pain in non-cancer context. Eighteen (11%)
references concerned specifically neuropathic pain treat-
ment in patients with cancer (Table 1). A large majority
(80%) of references were related to RCTs and meta-
analysis, systematic review, or review. According to
SIGN-50, 50 references (31%) could be classified as top
evidence level (15 systematic reviews and 35 RCTs with
a high number of patients).
Only 30 (18%) of the 163 references were shared
between at least two guidelines: 21 shared by two
guidelines; four by three guidelines; four by four
guidelines; and only one by five guidelines.
References specifically related to neuropathic pain in
patients with cancer are presented in Table 2. Among
these references specifically related to neuropathic pain
in patients with cancer, only four were shared by at least
two references.
Treatment for Neuropathic Pain in Patients
with Cancer Recommendations and Their
Evidence Grading in CPGs
Drugs recommended in selected CPGs are presented in
Table 3. Among these, only three classes were recom-
mended by all CPGs: tricyclic antidepressant drugs; a2d
agonists; and other anticonvulsant drugs. SNRI anti-
depressant drugs were recommended by four CPGs
(France 2010, Italy 2009, Norway 2007, and Spain).
Strong opioids, in combination with co-analgesic, were
proposed by five CPGs (France 2010, Italy 2009, the
Netherlands 2008-I, Norway 2007, and Spain).
However, the Netherlands 2008-II recommended not
using them, and three CPGs did not mention them (Italy
2006, U.K., and Norway 2009). Capsaicin plaster was
recommended by five guidelines (France 2010, the
Netherlands 2008-I, Norway 2007, Spain, and U.K.)
Table 1. Description of CPGs and Characteristics of the References Mentioned in the Section Treatment for
Neuropathic Pain in Patients with Cancer
Reference Topic Number of References Publication Year
Publication Type
Shared ReferencesSR+R RCT  60 RCT < 60 CPG Other
Neuropathic pain 116 1969–2007 20 34 49 8 5 22
Cancer neuropathic pain 18 1992–2008 4 1 8 0 5 4
Cancer pain 14 1980–2007 4 0 4 3 3 1
Acute and chronic pain 11 1999–2007 4 0 1 4 2 0
Other 4 2000–2004 2 0 0 0 2 3
Total 163 1969–2008 34 35 62 15 17 30
SR+R, Systematic Review,meta-analysis and review; RCT  60, randomized Controlled Trial with 60 or more patients; RCT < 60, Randomised Controlled Trial with < 60 patients; CPG,
Clinical Practice Guideline; Other, cohort study, observational study, case report, local statement; shared references, number of references which are mentioned in at least two
guidelines.
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and not mentioned in the others. Lidocaine 5% plaster
was recommended in three guidelines (France 2010, the
Netherlands 2008-I, and Spain) not recommended in two
guidelines (Norway2007 andU.K.) andnotmentioned in
others. Regarding more invasive therapeutic approaches,
only ketamine was recommended after indication con-
firmation by a pain specialist in four CPGs: Italy 2006,
the Netherlands 2008-I, Spain, and U.K. Ketamine was
not mentioned by the other CPGs, whereas systemic
lidocaine was not recommended in four CPGs (France
2010, Italy 2006 and 2009, the Netherlands 2008-I) or
not mentioned in other CPGs.
Focused analysis on amitriptyline, pregabalin, and
gabapentin is presented in Table 4. For amitriptyline,
evidence level for its recommendation varied from 1++
to four according the SIGN 50 criteria. For pregabalin,
evidence level for its recommendation varied also from
1++ to 4. For gabapentin, this level varied from 1++ to 2.
In accordance level of grading varied in the same way for
the three drugs. A large majority of CPGs indicated the
use rules of drugs but only three CPGs (France 2010, the
Netherlands 2008-II and Norway 2009) detailed sys-
tematically the side effects and contra-indications of
these drugs.
DISCUSSION
In the nine included CPGs on cancer pain or neuropathic
pain with at least one chapter on neuropathic pain in
patientswith cancer, all developed inEuropean countries,
163 references were used to support the given recommen-
dations on neuropathic pain treatment in patients with
cancer. Although the proportion of population-specific
referenceswas low (11%), itwas higher thanour previous
study on diagnosis and assessment of neuropathic pain in
patients with cancer (3%).7 Moreover, the mean level of
Table 2. Neuropathic Pain Treatment in Cancer References in Nine National CPGs from European Countries
Year Publication Type Title of the Reference First Author Publication
Shared
References
2008 RCT, 44* Amitriptyline in the treatment for chemotherapy-induced
neuropathic symptoms.
Kautio J Pain Symptom Manage –
2007 RCT, 36 Tramadol in the treatment for neuropathic cancer pain: a
double-blind, placebo-controlled study.
Arbaiza Clin Drug Investig –
2007 Clinical trial, 65 Gabapentin and an opioid combination vs. opioid alone
for the management of neuropathic cancer pain: a
randomized open trial.
Keskinboa J Pain Symptom Manage +(2 CPGs)
2006 Review How to use antidepressants and anticonvulsants as adjuvant
analgesics in the treatment for neuropathic cancer pain.
McDonald J Support Oncol –
2005 Clinical trial, 62 Gabapentin is effective in the treatment for cancer-related
neuropathic pain: a prospective, open-label study.
Ross J Palliat Med –
2004 RCT, 121 Gabapentin for neuropathic cancer pain: a randomized
controlled trial from the Gabapentin Cancer Pain Study Group.
Caraceni J Clin Oncol + (4 CPGs)
2004 Review Adjuvant analgesics in cancer pain management. Lussier Oncologist –
2003 Systematic review Ketamine as an adjuvant to opioids for cancer pain. Bell J Pain Symptom Manage –
2002 RCT, 16 Amitriptyline in neuropathic cancer pain in patients on
morphine therapy: a randomized placebo-controlled,
double-blind crossover study.
Mercadente Tumori +(2 CPGs)
2002 RCT, 51 Phase III evaluation of nortriptyline for alleviation of symptoms
of cis-platinum induced peripheral neuropathy
Hammack Pain –
2002 RCT, 13 Venlafaxine in neuropathic pain following treatment for
breast cancer.
Tasmuth Eur J Pain –
2001 Case report Gabapentine for pain control in patients with cancer wound
dressing care
Devulder J Pain Symptom Manage –
1999 Clinical trial, 593 Assessment and treatment for neuropathic cancer pain following
WHO guidelines.
Grond Pain –
1999 Clinical trial, 22 Gabapentin as an adjuvant to opioid analgesia for neuropathic
cancer pain.
Caraceni J Pain Symptom Manage +(2 CPGs)
1997 Review Neuropathic pain in patients with cancer: mechanisms, syndromes,
and clinical controversies.22
Martin J Pain Symptom Manage –
1992 RCT, 25 Phenytoin as a co-analgesic in cancer pain. Yajnik J Pain Symptom Manage –
1992 RCT, 11 A randomized double-blind crossover trial of intravenous
lidoca€ıne in
the treatment for neuropathic cancer pain
Bruera Cancer Treat Rep –
1989 RCT, 10 Trial of intravenous lidoca€ıne on painful neuropathy in
patients with cancer.
Elleman Clin J Pain –
RCT, randomized controlled trial; CPGs, clinical practice guidelines.
*Number of patients included in the trial.
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evidence ofused referenceswashigh (44%).Nevertheless,
few references were used in at least twoCPGs (18%), and
no reference was shared by all the CPGs.
All CPGs recommended the use of antidepressant
drugs, a2d agonists and others anticonvulsant drugs.
Proposal of these drugs in first line treatment is not
supported by high evidence level. For example, amitrip-
tyline is the oldest anti-neuropathic drug and well
investigated in non-cancer populations,18 but Merca-
dante et al.19 demonstrated the analgesic effects on
neuropathic pain of 50 mg of amitriptyline were small
and associated with side events in patients with cancer.
Similar results were found in another study related to
treatment for chemotherapy-induced neuropathic symp-
toms with amitriptyline.20
We also found diversity in recommendations con-
cerning strong opioids and more invasive approaches
such as ketamine. Such second line therapeutic
approaches were proposed by some CPGs, whereas they
were not mentioned at all in others. This shows a gap
between daily practice (wide utilization of ketamine or
lidocaine in cancer pain, not only in case of neuropathic
pain) and recommendations in part of the CPGs.
Ideally, high quality CPGs should describe adverse
events and risks of treatments. In the studied CPGs,
these were well described for strong opioids.7 However,
in the majority of the CPGs, adverse events of antide-
pressants or anticonvulsants as treatment for neuro-
pathic pain were not mentioned. Up to now, the benefit-
risk ratio of these drugs in patients with cancer is
unknown.19,21 Consequently, we recommend that CPGs
mention restrictions when study findings in non-cancer
populations are extrapolated to patients with cancer.
Clinical practice guidelines differ in terms of used
references, extrapolation techniques, and assigned levels
of evidence. The origin and the composition of the
guideline development groups seem to have influenced
the clinical recommendations, 22,23 which are based on
their clinical experiment and their choice of evidence-
based references.
Our results should be interpreted with caution. They
are merely based on available information in the CPGs.
Only one chapter per CPG concerned neuropathic pain
in patients with cancer. These results emphasize the lack
of robust references on the treatment for neuropathic
pain in cancer conditions. As we limited ourselves to
Europe, we were able to develop a detailed study
including all European countries. In the future, it would
be interesting to include CPGs from other continents.
Recommendations and Perspective
The majority of guideline development groups extra-
polated results of studies on non-cancer neuropathic
pain to recommendations for patients with cancer.
Consequently, these CPGs fail to address important
Table 3. Treatment for Neuropathic Pain in Patients with Cancer According to European National CPGs
Treatment for Neuropathic Pain
in Patients with Cancer France
Italy
2009
Italy
2006
The Netherlands
2008-I
The Netherlands
2008-II
Norway
2009
Norway
2007* Spain U.K.*
Paracetamol, NSAIDs,  0 0 0  0 0 0 0
Weak opioids (ie, dextropropoxyphene,
tramadol)
+ 0 0 0  0 0 0 0
Tricyclic Antidepressant drugs (ie, amitriptiline,
imipramine)
+ + + + + + + + +
SNRI Antidepressant drugs (ie, venlafaxine,
duloxetine)
+ + 0 0 0 0 + + 0
a2d agonists (ie, gabapentine, pregabaline) + + + + + + + + +
Others Anticonvulsant drugs (ie,
carbamazepine, valproate of sodium,
phenitoine)
+ + + + + + + + +
Corticosteroides  0 0  0 +  0 0
Opioids (ie, morphine, oxycodone) in
combination with coanalgesics
+ + 0 +  0 + + 0
Lidoca€ıne 5% plaster (only in case of
local neuropathic pain)
+ 0 0 + 0 0 –† + -
Capsaicin plaster (only in case of local
neuropathic pain)
+ 0 0 + 0 0 + + +
Ketamine 0 0 +‡ +‡ 0 0 0 +R +‡
Lidocaine, mexiletine     0 0 0 0 0
Cannabino€ıdes 0 0 0 0 0 0 0 0 
*The topic of the guideline concerned specifically the treatment for pain in cancer.
†No marketing in Norway.
‡Consultation with a pain or palliative care specialist (+): should be proposed, (): should not be proposed, (0): no information. R: refractory neuropathic pain.
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issues such as altered kinetics and side effect profiles in
these patients. We recommend creating specific recom-
mendations by an international expert group for the
treatment for neuropathic pain in patients with cancer
supported by targeted research in patients with cancer.
For this purpose, there is a need for research protocols
with prospective multicenter and multinational studies
in clinical practice comparing different treatment strat-
egies and to publish all studies whether the results
reported are positive or negative.
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